A local hospital is using new technology to remove liver cancer without invasive surgery. It’s a word that no one ever wants ...
Overall survival is no better for patients diagnosed with NMIBC who progress directly to metastasis.
Skin cancer is the most commonly diagnosed form of cancer in the United States and, according to the American Cancer ...
News Nation on MSN
Patrick Soon-Shiong’s cancer drug approved by Saudi FDA
Dr. Soon-Shiong is hopeful the Saudi Arabian FDA's approval of his cancer therapy drug, Anktiva, will lead to widespread ...
PEABODY, Mass., Nov. 17, 2025 /PRNewswire/ -- Privo Technologies today announced results from the CLN-004 Phase 2/3 (Cohort 1) trial evaluating PRV111, a nanoengineered, cisplatin-releasing patch for ...
ImmunityBio stock jumps after strong trial updates in bladder cancer and lymphoma, with enrollment ahead of schedule and FDA ...
Histotripsy is a non-invasive treatment, approved by the Food and Drug Administration (FDA) in 2023, that uses ultrasound energy to destroy liver tumors in a single outpatient procedure. This includes ...
ImmunityBio’s IBRX QUILT-2.005 trial tops enrollment forecasts; BLA filing targeted by year-end after positive ANKTIVA+BCG ...
Some cancers may not require immediate treatment, from prostate cancer to thyroid tumors. Medical experts share when ...
Approval of ANKTIVA was granted for BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ, with ...
ImmunityBio, Inc. (NASDAQ:IBRX) is one of the best penny stocks to buy for 2026. On December 16, ImmunityBio, Inc.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback